Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials

@article{Roustit2013Phosphodiesterase5IF,
  title={Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials},
  author={M. Roustit and S. Blaise and Y. Allanore and P. Carpentier and E. Caglayan and J. Cracowski},
  journal={Annals of the Rheumatic Diseases},
  year={2013},
  volume={72},
  pages={1696 - 1699}
}
Introduction Recent controlled trials have assessed the efficacy of phospodiesterase-5 (PDE-5) inhibitors in secondary Raynaud's phenomenon (RP). However, the conclusions are conflicting, and whether these drugs are effective remains unclear. The objective of this meta-analysis was to determine the efficacy of PDE-5 inhibitors on Raynaud's Condition Score (RCS) and frequency and duration of attacks. Methods A systematic review of articles was performed (sources included Medline, Embase, Web of… Expand
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Therapeutic implications from the pathogenesis of Raynaud’s phenomenon
  • A. Herrick
  • Medicine
  • Expert review of clinical immunology
  • 2017
In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks
Treatment options in Raynaud's phenomenon
Drug Treatment of Raynaud’s Phenomenon
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.
...
1
2
...